Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep 5;4(9):e243.
doi: 10.1038/bcj.2014.63.

Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups

S Ailawadhi  1 , A Swaika  1 , P Razavi  2 , D Yang  3 , A Chanan-Khan  1
Affiliations

Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups

S Ailawadhi et al. Blood Cancer J. .

Abstract

Second primary malignancies (SPMs) among multiple myeloma (MM) patients have been reported with an estimated incidence varying from 1 to 15%. We have previously reported that significant disparity exists in MM survival across patients of different ethnicities. We undertook a Surveillance Epidemiology and End Results-based analysis to describe the incidence of SPMs among MM patients of different ethnicities, to explore the variable impact that SPMs might have on MM outcomes of patients across racial subgroups. We found that the risk of developing SPMs among MM patients is variable depending on the patient's ethnic background. This warrants further exploration of the impact of SPMs on outcomes of MM patients across different racial subgroups, especially in the form of prospective data collection and analyses.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean age at diagnosis of MM and SPM, respectively by race.
Figure 2
Figure 2
Observed-to-expected (O/E) incidence of overall, all solid-organ and acute non-lymphocytic leukemia (ANLL) SPM in MM patients by race.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Law IP, Blom J. Second malignancies in patients with multiple myeloma. Oncology. 1977;34:20–24. - PubMed
    1. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB. The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med. 1979;301:743–748. - PubMed
    1. Cuzick J, Erskine S, Edelman D, Galton DAG. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. Br J Cancer. 1987;55:523–529. - PMC - PubMed
    1. Govindarajan R, Jagannath S, Flick JT, Vesole DH, Sawyer J, Barlogie B, et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol. 1996;95:349–353. - PubMed
    1. Olivanen T. Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study. Eur J Haematol. 2000;65:123–127. - PubMed